UBE2T and breast carcinoma: As shown in Fig. 6C–H, in breast cancer, lung adenocarcinoma, liver hepatocellular carcinoma, skin cutaneous melanoma, prostate adenocarcinoma and adrenocortical carcinoma, the survival time of the group with high expression of UBE2T was shorter than that of the group with low expression.